Home/Alpha Fusion/Yuichi Tomura, Ph.D., R.Ph.
YT

Yuichi Tomura, Ph.D., R.Ph.

Head of R&D

Alpha Fusion

Therapeutic Areas

Alpha Fusion Pipeline

DrugIndicationPhase
af-001 (TAH-1005)Thyroid Cancer (Radioiodine-Refractory)Phase 1
af-001Thyroid Cancer (Radioiodine-Naïve)Phase 1
af-002 (PSW-1025)Prostate Cancer (Refractory)IND-enabling
af-003Pan-CancerIND-enabling
Tanabe-Veneno ProgramUndisclosedExploratory
In-house ProgramUndisclosedExploratory